high dose tirzepatide study Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Tirzepatide for Obesity Treatment and

For individuals already taking GLP-1 medications who are not Amazon One Medical primary care patients, there are on-demand care prescription renewal services available, ensuring treatment continuity with appropriate medical oversight

With our expertise in bioanalysis, we help researchers, clinicians, and healthcare professionals gain valuable insights into the antioxidant defense systems and their role in human health

The TGA has just issued a new class-wide drug safety warning for: high-profile medicines used to treat diabetes and obesity Here is how the TGA of Australia is warning its populace: We have updated the product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists for two separate safety issues (see below)

Most patients see significant improvement within months by following dietary advice and medical guidance

Timing precision: Eat something small every 2.5-3 hours

Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes